To further investigate whether the therapeutic benefits of combined TRIM28 inhibition and anti-PD-1 extend to human NSCLC, we utilized a human lung adenocarcinoma cell line, H1299, in a humanized huHSC-NOG-EXL mouse model. Here, TRIM28 is linked to non-small cell lung carcinoma.